SE0402025D0 - Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent - Google Patents
Treatment of hyperproliferative disease with superantigens in combination with another anticancer agentInfo
- Publication number
- SE0402025D0 SE0402025D0 SE0402025A SE0402025A SE0402025D0 SE 0402025 D0 SE0402025 D0 SE 0402025D0 SE 0402025 A SE0402025 A SE 0402025A SE 0402025 A SE0402025 A SE 0402025A SE 0402025 D0 SE0402025 D0 SE 0402025D0
- Authority
- SE
- Sweden
- Prior art keywords
- superantigen
- hyperproliferative disease
- chemotherapeutic agent
- superantigens
- treatment
- Prior art date
Links
- 231100000617 superantigen Toxicity 0.000 title abstract 5
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402025A SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
US11/202,507 US7763253B2 (en) | 2004-08-13 | 2005-08-12 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
PCT/EP2005/008815 WO2006015882A2 (fr) | 2004-08-13 | 2005-08-12 | Traitement des maladies hyperproliférantes à l’aide de super-antigènes combinés à un autre agent anticancéreux |
EP05777870.6A EP1786449B1 (fr) | 2004-08-13 | 2005-08-12 | Traitement de maladies hyperprolifératives en utilisant superantigène en combinaison avec un agent cytostatique |
ES05777870.6T ES2547348T3 (es) | 2004-08-13 | 2005-08-12 | Tratamiento de enfermedades hiperproliferativas con un superantígeno en combinación con un agente citostático |
CA2575406A CA2575406C (fr) | 2004-08-13 | 2005-08-12 | Traitement des maladies hyperproliferantes a l'aide de super-antigenes combines a un autre agent anticancereux |
AU2005270336A AU2005270336B2 (en) | 2004-08-13 | 2005-08-12 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
US12/787,095 US8293243B2 (en) | 2004-08-13 | 2010-05-25 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402025A SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0402025D0 true SE0402025D0 (sv) | 2004-08-13 |
Family
ID=32960399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0402025A SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
Country Status (7)
Country | Link |
---|---|
US (2) | US7763253B2 (fr) |
EP (1) | EP1786449B1 (fr) |
AU (1) | AU2005270336B2 (fr) |
CA (1) | CA2575406C (fr) |
ES (1) | ES2547348T3 (fr) |
SE (1) | SE0402025D0 (fr) |
WO (1) | WO2006015882A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124886A (en) | 1997-08-25 | 2000-09-26 | Donnelly Corporation | Modular rearview mirror assembly |
US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
EP2343320B1 (fr) | 2005-03-25 | 2017-10-25 | GITR, Inc. | Anticorps contre gitr et leur utilisations |
GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
PL2120568T3 (pl) * | 2007-02-16 | 2018-03-30 | Celator Pharmaceuticals, Inc. | Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych |
ES2591281T3 (es) * | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
US20090076042A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched erlotinib |
WO2009045543A1 (fr) * | 2007-10-04 | 2009-04-09 | The Regents Of The University Of California | Traitement d'affections liées à un choc |
WO2011038417A2 (fr) | 2009-09-28 | 2011-03-31 | The Regents Of The University Of California | Procédés pour accélérer la cicatrisation des tissus et des plaies et réduire la tuméfaction et la formation de cicatrice |
EP2600901B1 (fr) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
CN103237558A (zh) | 2010-10-02 | 2013-08-07 | 加利福尼亚大学董事会 | 最小化肠功能障碍 |
CA2831613A1 (fr) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Administration et formulation d'acides nucleiques genetiquement modifies |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (fr) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
KR102427777B1 (ko) | 2012-06-26 | 2022-08-01 | 델 마 파마슈티컬스 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
WO2015051214A1 (fr) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucléotides codant pour un récepteur de lipoprotéines de faible densité |
US10314910B2 (en) * | 2016-01-10 | 2019-06-11 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
CN109998488B (zh) * | 2019-04-13 | 2022-08-02 | 中国医学科学院北京协和医院 | 克罗恩病和肠道溃疡型淋巴瘤的鉴别模型及构建方法 |
KR20220009428A (ko) | 2019-05-15 | 2022-01-24 | 네오티엑스 테라퓨틱스 엘티디. | 암 치료 |
CN115484978A (zh) | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | 使用免疫细胞治疗癌症的方法和组合物 |
JP2023545893A (ja) * | 2020-08-19 | 2023-11-01 | ▲蘇▼州易慕峰生物科技有限公司 | ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002117A (en) * | 1934-08-07 | 1935-05-21 | Bruce Watson J | Artificial bait |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5858363A (en) * | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
US6197299B1 (en) * | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
WO1993024136A1 (fr) * | 1991-01-17 | 1993-12-09 | Terman David S | Effets tumoricides des enterotoxines, superantigenes et composes apparentes |
US7220724B2 (en) * | 1993-10-22 | 2007-05-22 | University Of Southern California | Contortrostatin CN and methods for its use in preventing metastasis and other conditions |
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
CA2216622A1 (fr) * | 1996-11-25 | 1998-05-25 | Smithkline Beecham P.L.C. | Nouveaux composes |
US6713284B2 (en) * | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
AU748097B2 (en) * | 1997-07-21 | 2002-05-30 | Active Biotech Ab | Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents |
SE9902989D0 (sv) | 1999-08-24 | 1999-08-24 | Active Biotech Ab | Novel compounds |
US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
US6706505B1 (en) * | 2000-03-08 | 2004-03-16 | Amgen Inc | Human E3α ubiquitin ligase family |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
DE10210312A1 (de) | 2002-03-10 | 2003-12-24 | Frank Perabo | Superantigentherapie |
SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
US7776800B2 (en) | 2005-12-09 | 2010-08-17 | Afton Chemical Corporation | Titanium-containing lubricating oil composition |
-
2004
- 2004-08-13 SE SE0402025A patent/SE0402025D0/xx unknown
-
2005
- 2005-08-12 AU AU2005270336A patent/AU2005270336B2/en active Active
- 2005-08-12 ES ES05777870.6T patent/ES2547348T3/es active Active
- 2005-08-12 CA CA2575406A patent/CA2575406C/fr active Active
- 2005-08-12 EP EP05777870.6A patent/EP1786449B1/fr active Active
- 2005-08-12 WO PCT/EP2005/008815 patent/WO2006015882A2/fr active Application Filing
- 2005-08-12 US US11/202,507 patent/US7763253B2/en active Active
-
2010
- 2010-05-25 US US12/787,095 patent/US8293243B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1786449A2 (fr) | 2007-05-23 |
EP1786449B1 (fr) | 2015-07-01 |
US20100303836A1 (en) | 2010-12-02 |
WO2006015882A3 (fr) | 2007-04-19 |
CA2575406A1 (fr) | 2006-02-16 |
US7763253B2 (en) | 2010-07-27 |
AU2005270336A1 (en) | 2006-02-16 |
ES2547348T3 (es) | 2015-10-05 |
US20060057111A1 (en) | 2006-03-16 |
CA2575406C (fr) | 2016-06-21 |
US8293243B2 (en) | 2012-10-23 |
AU2005270336B2 (en) | 2011-11-24 |
WO2006015882A2 (fr) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0402025D0 (sv) | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | |
CY1120445T1 (el) | Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου | |
EA200970435A1 (ru) | Лечение общих расстройств развития | |
CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
WO2012094679A3 (fr) | Compositions et procédés pour délivrer aux tumeurs des agents se liant à l'oxygène avec une affinité élevée | |
TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
CY1111478T1 (el) | Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης | |
CY1115046T1 (el) | Καινουργια sirnas και μεθοδοι χρησης αυτων | |
EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
MY136604A (en) | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting celll proliferation | |
DK2484365T3 (da) | Sammensætninger og fremgangsmåde til behandling af neovaskulære sygdomme | |
EA200700686A1 (ru) | Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии | |
EA201391286A1 (ru) | Лечение солидных опухолей | |
BRPI0516177B8 (pt) | oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 | |
NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
WO2005094322A3 (fr) | Traitement efficace des tumeurs et du cancer a l'aide de la triciribine et de composes associes | |
MX2009002893A (es) | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). | |
DK1750716T3 (da) | Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin | |
WO2005117542A3 (fr) | Traitement du cancer du pancreas a l'aide de composes a base de vitamine d active, combine a d'autres traitements | |
DE602006019977D1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
JP2015514756A5 (fr) | ||
MX2009003039A (es) | Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer. | |
MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
ES2340842T3 (es) | Anticuerpos anti-apc no neutralizantes. | |
DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen |